Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9614 posts found.

anatomy-3003099_960_720

Stem cell therapy offers hope for spinal cord injuries

February 28, 2018 Research and Development biotech, drugs, pharma, pharmaceutical, stem cell, stem cell treatment

Scientists have brought the prospect of spinal cord injuries being able to be treated with stem cells one step closer, …
News
celgene_1_02

FDA refuses to review Celgene’s ozanimod in multiple sclerosis

February 28, 2018 Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …
News

AstraZeneca creates biotech spin-off, $250m in bank

February 28, 2018 Research and Development, Sales and Marketing AstraZeneca, Viela, biotech, drugs, pharma, pharmaceutical

Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely …
News
pharmafocus_march_2018_cover

Pharmafocus March 2018 is available to read online now!

February 28, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, brexit, drug safety, pharma, real world data

Though never truly out of vogue, the drug pricing debate has flared up again with the White House’s release of …
News
dna

Generation Bio backed with $100m financing round

February 28, 2018 Research and Development, Sales and Marketing Generation Bio, biotech, drugs, pharma, pharmaceutical

At the start of year, Generation Bio was revealed to the public, announcing that it had been developing gene therapies …
News
opioid_crisis

FDA to fight opioid crisis with wider access to medication-assisted treatment

February 27, 2018 Manufacturing and Production, Medical Communications, Research and Development Alex Azar, FDA, medication-assisted treatment, opioid crisis, opioids, pharma

The FDA is set to refocus its efforts in combating the United States’ opioid crisis. Speaking at a meeting of …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
News
tumour_growing_jan-chlebik-for-the-icr-2013

Lab-grown tumours able to predict drug efficacy

February 23, 2018 Medical Communications, Research and Development biotech, drugs, pharma, pharmaceutical

One of the key challenges facing the treatment of cancer is knowing whether a particular drug will work with an …
News

Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial

February 23, 2018 Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes

Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …
News
aaa

Insider Interview: Allergan’s R&D Chief on plans to be “the headache company”

February 22, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, David Nicholson, Insider Interview, migraine, pharma

Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the …
Feature
regeneron

Reports increasing of worrying side-effects with Regeneron’s Eylea

February 22, 2018 Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma

Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …
News
merckincweb

MSD poised to acquire viral immuno-oncology firm Viralytics for $394m

February 21, 2018 Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …
News
astrazeneca_logo_building

AZ licenses kidney drug from Ionis for $330m

February 21, 2018 Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical

AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
News
peanuts_nuts_snack_nutrition_healthy_nibble_decoration_close-842313

Aimmune’s peanut allergy candidate hits main endpoint at Phase 3

February 21, 2018 Research and Development Aimmune, peanut, peanut allergy, pharma

US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …
News
abbviehqe_004_low

AbbVie turns to tau for Alzheimer’s in $1.1bn deal

February 21, 2018 Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …
News
The Gateway to Local Adoption Series

Latest content

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026